These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10516677)

  • 21. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Indications for bone marrow and peripheral stem cell transplantation in malignant hematological diseases].
    Gratwohl A
    Ther Umsch; 1996 Feb; 53(2):152-7. PubMed ID: 8629266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intensive treatment of multiple myeloma].
    Harousseau JL
    Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem-cell transplantation in multiple myeloma.
    Gahrton G
    Wien Med Wochenschr; 1995; 145(2-3):52-4. PubMed ID: 7762254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
    Kiehl MG; Kraut L; Schwerdtfeger R; Hertenstein B; Remberger M; Kroeger N; Stelljes M; Bornhaeuser M; Martin H; Scheid C; Ganser A; Zander AR; Kienast J; Ehninger G; Hoelzer D; Diehl V; Fauser AA; Ringden O
    J Clin Oncol; 2004 Jul; 22(14):2816-25. PubMed ID: 15254049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
    Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
    Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic bone marrow transplantation in multiple myeloma.
    Gahrton G
    Pathol Biol (Paris); 1999 Feb; 47(2):188-91. PubMed ID: 10192887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
    Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
    Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
    Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
    Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.